Puhong Zhang

ORCID iD
https://orcid.org/0000-0003-4610-9848
  • Also known as
  • Show details Hide details
Dr. Zhang

Sources:
Puhong Zhang (2014-08-30)

  • Country
  • Show details Hide details
China

Sources:
Puhong Zhang (2016-01-24)

  • Keywords
  • Show details Hide details
NCD prevention and control

Sources:
Puhong Zhang (2014-08-30)

Biography

A/Prof. Puhong Zhang is a Senior Research Fellow at The George Institute for Global Health at Peking University Health Science Center. He completed his bachelor, master and doctor degree education in China before 2014 focusing on Preventive Medicine, Epidemiology and Biostatistics, and Cardiovascular Epidemiology, separately. Since graduation from Fuwai hospital in 2004, Dr. Zhang worked for Beijing CDC, Beijing Management Center for Community Health Service, China CDC and now The George Institute consecutively but all focus on chronic disease prevention and control. Although now he is supervising several programs on NCD in George, his research interests mainly focus on innovative mHealth and diabetes research. As the director of the China Center for mHealth Innovation (CCmHI) in George, Dr. Zhang is leading several research projects with the purpose of improving healthy lifestyles and control of body weight, diabetes and hypertension based on mHealth technologies. FoodSwitch is an app to help consumer select healthier packaged food by scanning the barcode. SMART Diabetes is a smartphone-based platform to help lay family members to support the diabetes control for patients with diabetes. KnowSalt has also been developed to help a family to reduce salt intake by estimating salt intake and sources for each family member, while 1000-Day is to facilitate pregnant women and medical staff on routine health management and decision support. As the former Head of Diabetes Research Program in George China, Dr. Zhang has been leading several studies in diabetes since 2011: 3C study supported by International Diabetes Federation to find the coverage, cost and care status of type 1 diabetes; ORBIT study supported by Sanofi to observe the practical use of basal insulin in real world China; DOSA study supported by ResMed Foundation to clarify the prevalence of obstructive sleep apnea (OSA) in patients with type 2 diabetes; DOSA2 supported by Beijing Science and Technology Bureau to establish a clinical pathway to screen, diagnose and treat OSA in hospitalized diabetes patients. Expect for the experience in NCD and mHealth research, Dr. Zhang has years of experience working in China CDC and Beijing Health Bureau. He is very familiar with the policy and culture, know very well the current situation and the reform of health system, understand the needs of health service consumers and providers, and has very good sense of developing research ideas.

Record last modified {{lastModifiedDate}}